contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

ChemoMetec specializes in the design, development, and production of patented instruments for cell counting and cell analysis. The company cooperates and statutes agreements with actors such as research institutes, universities, food companies, hospitals, and specialist clinics. Customers are found in a global market. The company was founded in 1997 and is headquartered in Alleröd, Denmark.

ChemoMetec

ANNOUNCEMENT NO. 303 24 March 2026 Adjustment of guidance for 2025/26 Over the past period, ChemoMetec's most important market, the North American market for cell and gene therapy, has been ...

ANNOUNCEMENT NO. 303 24 March 2026 Adjustment of guidance for 2025/26 Over the past period, ChemoMetec's most important market, the North American market for cell and gene therapy, has been affected by three factors that negatively affect the sales of our products: <ol><li>In the autumn of 2025, the US market and our customers were affected by the lockdown of the government apparatus, and subsequently there has been a continued general restraint among a number of customers, partly as a result of the geopolitical and macroeconomic uncertainty. This has led to prolonged decision-making processes, which for ChemoMetec creates uncertainty as to whether a number of large orders will be received and invoiced in the financial year 2025/26. </li><li>Our customers’ implementation of automating the production of cell and gene therapies as well as of the processes within bioprocessing has proven to be more time-consuming than expected, which is due to the fact that these are large global projects across departments and countries, which is why we have seen that validations, decisions, etc. are taking longer than expected. </li><li>Customers' increased interest in the XcytoMatic platform has contributed to a slowdown in sales of NC instruments and associated consumables. </li></ol> We do not face increasing competition in the market of cell counting automation, quite the opposite. ChemoMetec is involved in a continued large and growing number of automation projects, and we are consistently seeing confirmation that our XcytoMatic products are extremely attractive and competitive. We therefore expect ChemoMetec's position to be further strengthened with the upcoming introduction of the new software platform XM Octopus. Based on the above, revenue of DKK 490-520 million is now expected in the financial year 2025/26 against the most recently announced DKK 565-580 million, while EBITDA is expected to be in the range of DKK 260-285 million compared to the most recently announced DKK 320-335 million. Additional Information Martin Helbo Behrens, CEO Tel.: (+45) 48 13 10 20 Kim Nicolajsen, CFO Tel.: (+45) 48 13 10 20 About ChemoMetec A/S ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies. ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to <a href="https://www.globenewswire.com/Tracker?data=sHyM2B3JahrE38bqh6ud24YN1f4jDrXv9Xqvf55u7sJ2r4A75HOuLne8blUO_DbxzPrxaaPcvDWzjlng7KxvRee0uD-1pgRDFw-rFM01rXU=">www.chemometec.com</a>. <img alt="" src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE3MTkyNSM0MDIzNjM1NTAjMjAxOTIyNA=="> <img alt="" src="https://ml-eu.globenewswire.com/media/NzhiMTc4NmYtZDA4YS00ZDZmLWE2ZjItNDE3NjNhNzBmMWU5LTEwMzA3OTctMjAyNi0wMy0yNC1lbg==/tiny/Chemometec-A-S.png">

Adjustment of guidance for 2025/26

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up

Return on capital (ROE, ROI, ROIC, RONIC)

Balance sheet, debt leverage and risks